Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 5.7%

Share on StockTwits

Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) fell 5.7% during mid-day trading on Tuesday . The company traded as low as $1.94 and last traded at $1.99, 1,057,762 shares changed hands during trading. A decline of 27% from the average session volume of 1,457,918 shares. The stock had previously closed at $2.11.

A number of research firms have issued reports on ACRS. William Blair reiterated a “buy” rating on shares of Aclaris Therapeutics in a report on Friday, October 11th. Leerink Swann upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, October 22nd. Svb Leerink reiterated an “outperform” rating on shares of Aclaris Therapeutics in a report on Thursday, January 2nd. Zacks Investment Research cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 8th. Finally, ValuEngine upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $6.67.

The company has a market cap of $87.33 million, a P/E ratio of -0.49 and a beta of 1.00. The company has a fifty day moving average price of $1.83 and a two-hundred day moving average price of $1.58. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.73 and a current ratio of 3.73.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.80). The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. Research analysts anticipate that Aclaris Therapeutics Inc will post -1.78 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in ACRS. Marshall Wace LLP bought a new position in shares of Aclaris Therapeutics in the 1st quarter valued at about $103,000. JPMorgan Chase & Co. grew its holdings in shares of Aclaris Therapeutics by 66.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 408,262 shares of the biotechnology company’s stock valued at $870,000 after acquiring an additional 162,458 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Aclaris Therapeutics by 18.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 206,589 shares of the biotechnology company’s stock valued at $453,000 after acquiring an additional 32,759 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Aclaris Therapeutics by 63.7% in the 2nd quarter. Renaissance Technologies LLC now owns 699,580 shares of the biotechnology company’s stock valued at $1,532,000 after acquiring an additional 272,200 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of Aclaris Therapeutics by 58.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 90,867 shares of the biotechnology company’s stock valued at $199,000 after acquiring an additional 33,646 shares in the last quarter. Institutional investors own 74.26% of the company’s stock.

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Story: What member countries make up the G-20?

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.